Allstocks.com's Bulletin Board Post New Topic  New Poll  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » Pink Sheet Stocks » HBRM

 - UBBFriend: Email this page to someone!    
Author Topic: HBRM
luckylindy
Member


Member Rated:
4
Icon 1 posted      Profile for luckylindy     Send New Private Message       Edit/Delete Post   Reply With Quote 
HBRM NEWS: Herborium Group, Inc. Focuses on a Lucrative Botanical Therapeutics Market
Buzz up! 0 Print
Companies:HERBORIUM GROUP Related Quotes
Symbol Price Change
HBRM.PK 0.0248 +0.0028


{"s" : "hbrm.pk","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""} Press Release Source: Herborium Group, Inc. On Friday May 28, 2010, 4:00 pm
SADDLE BROOK, NJ--(Marketwire - 05/28/10) - Herborium Group, Inc. (Pinksheets:HBRM - News) (http://www.herborium.com/), a botanical therapeutics® company that develops, licenses and markets all natural, herbal medicinal products, has focused its efforts on developing aggressive routes of taping into $33 billion over the counter alternative medicine market in the USA and over a trillion USD global market for alternative and complementary medicine.

The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage.

Herborium pipeline of botanical therapeutics in the sectors of dermatology (Acne -- global market is over 55 Billion USD and over 60 million Americans are diagnosed and affected yearly by different forms of acne -- http://www.acnease.com/), women's and men's health, including BPH (benign prostate hyperplasia affects over half of male population at the age of 50+) and liver health, belong to the most growing category of CAM products (self care costs) that reached $22 Billion in the US last year with majority going to purchase of non-vitamin, and non-mineral products.

"With the conversion of such factors as health economics, directing consumers to spend money on prevention and on non ethical products (lower insurance coverage) and to pharmaceutical companies being forced to remove drugs from the market for safety reasons (La Roche and Accutane for acne or Vioxx for pain), Herborium is ideally positioned to take advantage of those emerging market opportunities," said Dr. Agnes P. Olszewski, President of Herborium Group. "During last four months we have focused our activities on preparing to penetrate new markets with our existing products including targeting of foreign markets. We have signed or are in final stage of negotiating new distribution agreements in the USA and abroad that will greatly increase our customer base. We expect that our bottom line will significantly benefit from those initiatives in 2010 and 2011," continues Dr. Olszewski.

"We are also planning to introduce new and complementary products. We are especially excited about expected product line extension in the field of dermatology with a product targeting acne," adds Dr. Olszewski

"While securing additional resources we plan to address needs of consumers and health providers that look for highly efficient, proven safe and effective all natural alternatives in treatment and prevention of number of health problems and concerns," concludes Dr. Olszewski

About Herborium Group, Inc.
Herborium Group, Inc., a botanical therapeutics® company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium harvests its therapeutic candidates from Traditional Chinese Medicine and utilizes Western regulatory, clinical and marketing strategies to successfully introduce the products to the Western markets. The company secured a pipeline of botanical ingredients based products in the areas of dermatological needs, Prostate Health (BPH), Liver Diseases, Women's Health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, surgical procedures, and other problems. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the forms 10-Q.

Contact:
Company Contact:Dr. Agnes P. OlszewskiPresident & CEOTel: (201) 647.3757

Posts: 809 | From: florida | Registered: Dec 2008  |  IP: Logged | Report this post to a Moderator
luckylindy
Member


Member Rated:
4
Icon 1 posted      Profile for luckylindy     Send New Private Message       Edit/Delete Post   Reply With Quote 
HBRM: http://smallcapsociety.com/hbrm.php
Posts: 809 | From: florida | Registered: Dec 2008  |  IP: Logged | Report this post to a Moderator
g_money
Member


Rate Member
Icon 1 posted      Profile for g_money     Send New Private Message       Edit/Delete Post   Reply With Quote 
HBRM low float - will move fast when it goes:

FLOAT 41,960.487

--------------------
All material posted by this poster is for informational purposes only

Posts: 213 | Registered: Dec 2008  |  IP: Logged | Report this post to a Moderator
g_money
Member


Rate Member
Icon 1 posted      Profile for g_money     Send New Private Message       Edit/Delete Post   Reply With Quote 
this stock is finally getting some 'due attention' -- the sales projections are outstanding for 2010 & 2011

things are just getting started here

we get some killer volume on Tuesday and this could break resistance levels and fly by 035 and its wide open after that

--------------------
All material posted by this poster is for informational purposes only

Posts: 213 | Registered: Dec 2008  |  IP: Logged | Report this post to a Moderator
scooz
Member


Rate Member
Icon 1 posted      Profile for scooz     Send New Private Message       Edit/Delete Post   Reply With Quote 
http://www.microcapreports.com/herborium
Posts: 598 | Registered: Mar 2005  |  IP: Logged | Report this post to a Moderator
scooz
Member


Rate Member
Icon 1 posted      Profile for scooz     Send New Private Message       Edit/Delete Post   Reply With Quote 
Based on these public estimates the stock price of HBRM could soar up 790% in the near term and more than 2,327% this year.

With 68% margins and 200 million shares outstanding at 19X EPS…

Target Share Price = $.67 for 2010 and $1.34 for 2011

Herborium, Inc.’s (HBRM) business plan is to raise expansion capital for new healthcare market opportunities and reach $10 million in sales for 2010 with a gross profit margin of 68%. Then in 2011 the company’s projections are for $20 million in sales with a similar high gross profit margin.

Posts: 598 | Registered: Mar 2005  |  IP: Logged | Report this post to a Moderator
luckylindy
Member


Member Rated:
4
Icon 1 posted      Profile for luckylindy     Send New Private Message       Edit/Delete Post   Reply With Quote 
HBRM Microcap report:
http://www.microcapreports.com/herborium

Posts: 809 | From: florida | Registered: Dec 2008  |  IP: Logged | Report this post to a Moderator
arizonagold
Member


Member Rated:
4
Icon 1 posted      Profile for arizonagold     Send New Private Message       Edit/Delete Post   Reply With Quote 
HBRM - Herborium Group, Inc. (PINKSHEETS: HBRM) (www.herborium.com), a botanical therapeutics(R) company that develops, licenses and markets all natural, herbal medicinal products.

This was up Friday. Don't forget to check it out first thing Tuesday Morning.

Posts: 143 | Registered: Apr 2010  |  IP: Logged | Report this post to a Moderator
arizonagold
Member


Member Rated:
4
Icon 1 posted      Profile for arizonagold     Send New Private Message       Edit/Delete Post   Reply With Quote 
HBRM - Last Price (USD) $0.0248
Change ▲ 0.0028 (12.73%)

This looked good Friday. Should continue Tuesday after the holiday. IMO

Posts: 143 | Registered: Apr 2010  |  IP: Logged | Report this post to a Moderator
luckylindy
Member


Member Rated:
4
Icon 1 posted      Profile for luckylindy     Send New Private Message       Edit/Delete Post   Reply With Quote 
60 Million people with acne in the United States need a new over the counter skin care medication now that Accutane® has been taken off the market.

Herborium Group, Inc. (HBRM) owns the patent to AcnEase® which is an FDA compliant botanical drug product shown to be a leading natural, safe and effective treatment for acne problems.
Now this $3.3 billion market in the US will be seeking out alternatives that can be supplied by Herborium’s AcnEase®. The company has been diligently setting up distribution networks in order to tap the $50 billion world-wide market for acne medication as well.

AcnEase® is one of many products that Herborium sells globally to high growth niches in the $250 billion dollar natural and alternative health sector.$250 Billion Global Market for Natural Products
United States: $60 Billion
European Union: $50 Billion
United Kingdom: $25 Billion

Posts: 809 | From: florida | Registered: Dec 2008  |  IP: Logged | Report this post to a Moderator
Peaser
Member


Icon 1 posted      Profile for Peaser     Send New Private Message       Edit/Delete Post   Reply With Quote 
From keith68 on I-Hub:

this stock is being pumped:::

from microcap website they have 8 million shares to dump::::

http://www.microcapreports.com has not been compensated for this report however is an accredited investor and has purchased 10 million shares of AMSZ and 8 million shares of HBRM from a 3rd party debt holder from a non-controlling, non-affiliated 3rd party. We intend to sell our shares into market which could negatively affect the stock price. Investing in penny stocks is very risky and we invite anyone to please review the information provided by the SEC pertaining to penny stock rules http://www.sec.gov/

--------------------
Buy Low. Sell High.

Posts: 10736 | From: The Land Of The Giants | Registered: Feb 2005  |  IP: Logged | Report this post to a Moderator
luckylindy
Member


Member Rated:
4
Icon 1 posted      Profile for luckylindy     Send New Private Message       Edit/Delete Post   Reply With Quote 
Based on these public estimates the stock price of HBRM could soar up 790% in the near term and more than 2,327% this year.

With 68% margins and 200 million shares outstanding at 19X EPS…

Target Share Price = $.67 for 2010 and $1.34 for 2011

Herborium, Inc.’s (HBRM) business plan is to raise expansion capital for new healthcare market opportunities and reach $10 million in sales for 2010 with a gross profit margin of 68%. Then in 2011 the company’s projections are for $20 million in sales with a similar high gross profit margin.

Posts: 809 | From: florida | Registered: Dec 2008  |  IP: Logged | Report this post to a Moderator
luckylindy
Member


Member Rated:
4
Icon 1 posted      Profile for luckylindy     Send New Private Message       Edit/Delete Post   Reply With Quote 
News ,,,,,
(OTC: HBRM) Launches in the Trillion Dollar Global Alternative Medicine Sector

NEW YORK, NY -- (Marketwire)
06/01/10
Herborium Group, Inc. (PINKSHEETS: HBRM) announced that they are focusing their efforts on developing aggressive routes to tapping into the over the counter alternative medicine and complementary medicine market.

Plants have been used as a source of medicine throughout history and continue to serve as the basis for many pharmaceuticals used today. Although the modern pharmaceutical industry was born from botanical medicine, synthetic approaches to drug discovery have become standard. However, this modern approach has led to a decline in new drug development in recent years and a growing market for botanical therapeutics that are currently available as dietary supplements, drugs, or botanical drugs. Herborium initially aims to take on some of the most wide reaching afflictions that affect Americans, acne and benign prostate hyperplasia (BPH). These two focuses open up a 77 billion dollar market.

For more information, please visit www.smallcapsociety.com/hbrm.php

Other active stocks are Simcere Pharmaceutical Group (NYSE: SCR), China Sky One Medical (NASDAQ: CSKI) and Tianyin Pharmaceutical Co (AMEX: TPI)

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.


Eric Jensen

www.ionewswire.com

Posts: 809 | From: florida | Registered: Dec 2008  |  IP: Logged | Report this post to a Moderator
marinamel
Member


Rate Member
Icon 1 posted      Profile for marinamel     Send New Private Message       Edit/Delete Post   Reply With Quote 
Great news out this morning.....looks like HBRN is going to be a winner imo.

Herborium initially aims to take on some of the most wide reaching afflictions that affect Americans, acne and benign prostate hyperplasia (BPH). These two focuses open up a 77 billion dollar market

Posts: 348 | From: in the sun! | Registered: Dec 2008  |  IP: Logged | Report this post to a Moderator
luckylindy
Member


Member Rated:
4
Icon 1 posted      Profile for luckylindy     Send New Private Message       Edit/Delete Post   Reply With Quote 
Tuesday, June 01, 2010 8:54:39 AM

Investor Clueso Subsribers,

InvestorClueso is pleased to alert our subscribers to Herborium Group, Inc. (HBRM) which is poised to become a leading company in the Natural Healthcare Alternative market.

Herborium Group, Inc. (www.herborium.com), a botanical therapeutics(R) company that develops, licenses and markets all natural, herbal medicinal products, has focused its efforts on developing aggressive routes of taping into $33 billion over the counter alternative medicine market in the USA and over a trillion USD global market for alternative and complementary medicine.

The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage.

Herborium pipeline of botanical therapeutics in the sectors of dermatology (Acne -- global market is over 55 Billion USD and over 60 million Americans are diagnosed and affected yearly by different forms of acne -- www.acnease.com), women's and men's health, including BPH (benign prostate hyperplasia affects over half of male population at the age of 50+) and liver health, belong to the most growing category of CAM products (self care costs) that reached $22 Billion in the US last year with majority going to purchase of non-vitamin, and non-mineral products.

It is expected that in 2010, 65% of doctors in the US will recommend herbal or alternative medicinal products and 67% of the US population will use natural medications or alternative therapies. Big Pharma currently lacks a pipeline in this sector.

AcnEase? is one of many products that Herborium sells globally to high growth niches in the $250 billion dollar natural and alternative health sector.

The company has been diligently setting up distribution networks in order to tap the $50 billion world-wide market for acne medication as well.

Herborium, Inc.?s (HBRM) business plan is to raise expansion capital for new healthcare market opportunities and reach $10 million in sales for 2010 with a gross profit margin of 68%. Then in 2011 the company?s projections are for $20 million in sales with a similar high gross profit margin.

Herborium Group, Inc., (HBRM) is a novel botanical therapeutics? company focused on developing, licensing, and marketing of proprietary, botanical based medicinal products, targeting unmet medical needs. The Company responds to both consumers and healthcare professionals demand for safe, efficacious, all natural medicinal options for treatment and prevention of selected diseases and health concerns.

The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The potential for this market assesses for over $125 Billion in the USA and UK alone.

This new market is presently positioned for exponential growth since it represents a compelling response to changing needs of a healthcare sector. For the industry, botanical therapeutics provide a value added approach based on product differentiation, higher profit margins, and intellectual property protection with a lower risk and regulatory burden and lower cost. Nutraceuticals (supplements) face increasing FDA and market scrutiny, with massive competitive pressures. To meet the needs of this new growing market opportunity for a diverse spectrum of botanically based drugs, along with complementary and non-traditional therapies, Herborium introduces its own botanical therapeutics? defined as ?bridge products?, an emerging category of natural medicines whose safety and efficacy are validated through clinical studies.

Advantage
Herborium offers a robust business model designed to capitalize on the changing landscape in the healthcare sector spearheaded by novel regulatory, market and technological trends, and the cost advantage of natural medicinal products. Herborium?s unique blend of management?s expertise, clinical and regulatory know how in the US, Europe and PRC, diversified proprietary Botanical Therapeutics? portfolio and innovative marketing strategies provide for high-value, high-return opportunity and a strong entry barrier for potential competitors.

Mission
Herborium strives to become the Leader in developing and marketing novel, safe and effective, proprietary botanical therapeutics? (botanical based medicines), and innovative support content which target selected, unmet medical needs for disease treatment, management, and prevention.

The Company?s business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium harvests its therapeutic candidates from Traditional Chinese Medicine and utilizes Western regulatory, clinical and marketing strategies to successfully introduce the products into Western markets.

Company Accomplishments
?Technology Ownership (IP)

?Exclusive Distribution Rights

?Exclusive License

Posts: 809 | From: florida | Registered: Dec 2008  |  IP: Logged | Report this post to a Moderator
luckylindy
Member


Member Rated:
4
Icon 1 posted      Profile for luckylindy     Send New Private Message       Edit/Delete Post   Reply With Quote 
HBRM Sweet Chart:http://investorshub.advfn.com/boards/read_msg.aspx?message_id=50794634
Posts: 809 | From: florida | Registered: Dec 2008  |  IP: Logged | Report this post to a Moderator
luckylindy
Member


Member Rated:
4
Icon 1 posted      Profile for luckylindy     Send New Private Message       Edit/Delete Post   Reply With Quote 
Wednesday, June 02, 2010 8:59:56 AM

Good morning subscribers. This morning we are still buzzing over Herborium Group Inc., HBRM.PK. The company is gaining traction in the market place with investors. We had one question. Do their products work? Well, we did some digging to find out what the reviews were saying. What we found out was that they do work. AcnEase is their flagship product so we are bringing you reviews of it this morning. Read on and make up your own mind to the efficacy of the product.

The company is stepping into the acne arena armed with a product that effectively treats the diseased area without the use of a topical treatment. No creams or ointments to apply multiple times daily.

The market for OTC acne treatments alone was projected to pass the 550 million dollar mark by the year 2008. This dollar amount reperesents nearly 17% of the OTC medicated skin care market.

http://www.majormarketprofiles.com/report_print.asp?country=US&docid=26585&s=sna p


As a population, the USA has the largest percentage of overweight teens and young adults, those most likely to contract acne through poor diet alone.

As you can see, the market demand for AcnEase, coupled with the fact it really works, makes for an easy entry for Herborium Group to step onto the center stage as a leading provider for over the counter skin care treatment.

http://www.aragonproducts.com/theproducts.cfm?master=7566

The science behind AcnEase. AcnEase is a proprietary herbal acne treatment that was developed based on principles of Traditional Chinese Medicine and modern herbaceutical and pharmacological science. This all natural product is formulated with a Patented and Trade Secret protected blend of the highest quality herbal extracts.

The ability of AcnEase to serve as a natural acne treatment and to provide a natural acne cure is assured by extensive testing and strictly controlled manufacturing conditions. The ratio of the ingredients, the selection of herbs and the method of extraction are key factors in assuring the efficacy of AcnEase as a premium natural acne treatment.

Benefits: This unique acne treatment works in several ways: AcnEase prevents the forming of new pimples, whiteheads and blackheads and significantly improves symptoms associated with Adult Acne, Cystic Acne, Teen Acne and Body Acne.

AcnEase also reduces facial flushing and the incidence of blepheritis (itchy gritty eyes) and gastric reflux (heartburn), symptoms often associated with Rosacea.

http://www.onlineacneinfo.org/acne-product-reviews/acnease-review/

Get Rid of Acne from the Inside Out with AcnEase

While there are many products out there that are supposed to treat the acne problem, unfortunately not all of them are effective. In fact, some acne treatments actually end up doing more harm than good to your skin. For this reason, more and more people are beginning to turn to some of the natural acne treatments that are available. One excellent natural treatment out there that has proven to be very effective at treating acne is the product AcnEase. There are a variety of reasons that this products is definitely one of the best.

The Acne Problem is Properly Addressed

One of the reasons that AcnEase is such a great acne product is because it actually properly addresses the acne problem. There are many different products out there that only deal with treating the symptoms of acne; however, AcnEase actually works to get to the bottom of the problem. Instead of treating acne topically, this product treats the acne from the inside out and actually helps to balance out the body on the inside so that acne is no longer a problem that has to be dealt with. Although it can take a couple weeks to start showing results, the results are usually long lasting.


AcnEase Review

Acne problems are worse. They do not only damage your skin, but spoils your life as well. Several products have been sold in the market to treat this problem; but nothing came as close as AcnEase in treating acne infection. Find out more about this product by reading the review below.

http://hubpages.com/hub/acnease-review


Micro Cap Reports

http://www.microcapreports.com

June 2nd, 2010

Posts: 809 | From: florida | Registered: Dec 2008  |  IP: Logged | Report this post to a Moderator
luckylindy
Member


Member Rated:
4
Icon 1 posted      Profile for luckylindy     Send New Private Message       Edit/Delete Post   Reply With Quote 
HBRM: http://clicks.aweber.com/y/ct/?l=M4L5F&m=JQdbF9xJw7QhsJ&b=FtqcJM4wigp3wIqeFgj5BA
Posts: 809 | From: florida | Registered: Dec 2008  |  IP: Logged | Report this post to a Moderator
luckylindy
Member


Member Rated:
4
Icon 1 posted      Profile for luckylindy     Send New Private Message       Edit/Delete Post   Reply With Quote 
HBRM AH NEWS:
Herborium Group Commences AcnEase(R) Retail Sales
AcnEase(R) Now Available in New York Dermatology Clinics

SADDLE BROOK, NJ, Jun 02, 2010 (MARKETWIRE via COMTEX) -- Herborium Group, Inc., (PINKSHEETS: HBRM), a Botanical Therapeutics(TM) company, today announced it has now successfully secured direct consumer points-of-sale for its flagship product, AcnEase(R), with a recognized group of New York dermatological clinics.

"Acceptance of AcnEase by board certified dermatologist to be sold in the clinics is a major third-party validation of the therapeutic value of our product, and is an important cornerstone in building the AcnEase(R) brand," commented Dr. Agnes P. Olszewski, Herborium Group's president and chief executive officer.

AcnEase(R) is a proprietary, all herbal, systemically acting botanical therapeutic targeting acne symptom in both females and males of all ages, and has been proven safe and effective through clinical testing. Test results have demonstrated that in adolescent acne, approximately 95% of patients responded positively to AcnEase. In individuals above age 31, the level of effectiveness was 80%. The overall positive response rate to AcnEase was 91%. After more than five years of online sales, Herborium has consistently registered over 95% consumer satisfaction rating (www.acnease.com).

Dr. Olszewski continued, "Expanding beyond e-commerce (internet sales) to direct consumer points-of-sale is an important milestone in our overall plan to increase AcnEase sales and brand recognition and grow market share within the US 3.5 billion over the counter medicated skin care market

"With the current surge in sales of over-the-counter nutritional and health supplements, combined with Hoffmann-La Roche Inc.'s announcement to discontinue marketing of its leading treatment for severe acne, Accutane(R) (isotretinoin), and Herborium's AcnEase product's demonstrated and documented over five year history of safe and effective acne treatment, I firmly believe we have the right product, at the right time, for over 50 million acne sufferers in the USA.

"Having successfully launched our direct-to-consumer sales strategy with AcnEase in the US market , we intend to replicate this strategy to the extent justified "by market conditions" in International markets, while we prepare our next product sales initiative to access the US cosmeceutical market expected to potentially reach over $16 billion by 2010.

"Herborium is committed to continue developing a global brand with a strong international distribution network, and the acceptance of AcnEase by the dermatological community is a key development in both product branding and sales growth strategies," Dr. Olszewski concluded.

About Herborium Group, Inc.

Herborium Group, Inc., a botanical therapeutics(R) company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium harvests its therapeutic candidates from Traditional Chinese Medicine and utilizes Western regulatory, clinical and marketing strategies to successfully introduce the products to the Western markets. The company secured a pipeline of botanical ingredients based products in the areas of dermatological needs, Prostate Health (BPH), Liver Diseases, Women's Health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, surgical procedures, and other problems. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce.

One of our most important responsibilities is to communicate with shareholders in an open and direct manner. Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends." We cannot promise future returns. Our statements reflect our best judgment at the time they are issued, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events. Adino Energy Corporation urges investors to review the risks and uncertainties contained within its filings with the Securities and Exchange Commission.


Company Contact:
Dr. Agnes P. Olszewski
President & CEO
(201) 647-3757


SOURCE: Herborium Group, Inc.

Posts: 809 | From: florida | Registered: Dec 2008  |  IP: Logged | Report this post to a Moderator
luckylindy
Member


Member Rated:
4
Icon 1 posted      Profile for luckylindy     Send New Private Message       Edit/Delete Post   Reply With Quote 
Thursday, June 03, 2010 8:37:42 AM

Good morning investors. We are still buzzing about Herborium Group Inc., HBRM.PK. The company released tremendous news at the bell on Wednesday that announced to the public that they had acquired direct point of sale sites in dermatological clinics in the New York City area.

http://finance.yahoo.com/news/Herborium-Group-Commences-iw-1052859751.html?x=0&. v=1

HBRM.PK traded up yesteray closing the day at $.0275, a gain of nearly 6% on heavy volume of 2.7 million shares. That sent the company to it's fourth day of higher closes day over day. This trend looks to continue with the news released at the bell yesterday.

http://stockcharts.com/h-sc/ui?s=hbrm

The flagship product for Herborium Group Inc. is AcnEase®, a clinically tested and proven effective over the counter acne treatment for people of all ages that are afflicted with acne.

AcnEase® is a proprietary, all herbal, systemically acting botanical therapeutic targeting acne symptom in both females and males of all ages, and has been proven safe and effective through clinical testing. Test results have demonstrated that in adolescent acne, approximately 95% of patients responded positively to AcnEase. In individuals above age 31, the level of effectiveness was 80%. The overall positive response rate to AcnEase was 91%. After more than five years of online sales, Herborium has consistently registered over 95% consumer satisfaction rating.

http://www.acnease.com

http://www.aragonproducts.com/theproducts.cfm?master=7566

http://www.onlineacneinfo.org/acne-product-reviews/acnease-review/

http://hubpages.com/hub/acnease-review

http://www.herborium.com/Investor_Relations.html

As you can see, AcnEase® has been tested for over 5 years and has proven to be a safe, over the counter alternative to the Hoffman-LaRouche product, Accutane, which will soon no longer be marketed by the pharmaceutical giant.

With clinical trials comes the need for management to oversee them. The company's leadership team has over 100 years experience in the pharmaceutical, bio tech and drug manufacturing indutries.

Dr. Agnes P. Olszewski Ph.D, MBA. Founder & CEO - 20+ years experience in business strategy and global marketing with private and public companies

Dr. James P. Gilligan Ph.D. Co-Founder & COO - 25+ years experience in biotechnology, drug development, manufacturing, clinical testing

Dr. Alhua Qi, MD and TCM/MD, VP Traditional Chinese Medicine - 30 years TCM drug development clinical practice, originator of acne and liver formulas.

John E. Donahue, Controller/SEC Advisor - 25+ years experience corporate finance, M&A, public accounting

Lawrence Woo, Director; Asia Business Advisor - Past President Pfizer Greater China , President Wyeth Pharmaceutical China


The staff at Micro Cap Reports likes what we see so far and will continue to bring you the most up to date and comprehensive coverage of Herborium Group Inc. as soon as news becomes available.

Micro Cap Reports

http://www.microcapreports.com

Posts: 809 | From: florida | Registered: Dec 2008  |  IP: Logged | Report this post to a Moderator
luckylindy
Member


Member Rated:
4
Icon 1 posted      Profile for luckylindy     Send New Private Message       Edit/Delete Post   Reply With Quote 
Investor Clueso Subsribers,

We LOVED the AH news on HBRM yesterday! HBRM: Successfully secured direct consumer points-of-sale for its flagship product, AcnEase®.

The stock is trading very nicely with steady accumulation. With a relatively small float for the price, we believe HBRM has tremendous potential. Volume is always key in trading any stock and HBRM is definately attracting significant volume these days.

HBRM Share Structure:
May 7th, 2010
O/S 147,470,708
FLOAT 41,960.487
RESTRICTED 105,510,221

Herborium Group Commences AcnEase(R) Retail Sales
AcnEase(R) Now Available in New York Dermatology Clinics
Jun 2, 2010 3:00:00 PM

Herborium Group, Inc., (HBRM), a Botanical Therapeutics? company, today announced it has now successfully secured direct consumer points-of-sale for its flagship product, AcnEase®, with a recognized group of New York dermatological clinics.

"Acceptance of AcnEase by board certified dermatologist to be sold in the clinics is a major third-party validation of the therapeutic value of our product, and is an important cornerstone in building the AcnEase® brand," commented Dr. Agnes P. Olszewski, Herborium Group's president and chief executive officer.

AcnEase® is a proprietary, all herbal, systemically acting botanical therapeutic targeting acne symptom in both females and males of all ages, and has been proven safe and effective through clinical testing. Test results have demonstrated that in adolescent acne, approximately 95% of patients responded positively to AcnEase. In individuals above age 31, the level of effectiveness was 80%. The overall positive response rate to AcnEase was 91%. After more than five years of online sales, Herborium has consistently registered over 95% consumer satisfaction rating (www.acnease.com).

Dr. Olszewski continued, "Expanding beyond e-commerce (internet sales) to direct consumer points-of-sale is an important milestone in our overall plan to increase AcnEase sales and brand recognition and grow market share within the US 3.5 billion over the counter medicated skin care market

"With the current surge in sales of over-the-counter nutritional and health supplements, combined with Hoffmann-La Roche Inc.'s announcement to discontinue marketing of its leading treatment for severe acne, Accutane® (isotretinoin), and Herborium's AcnEase product's demonstrated and documented over five year history of safe and effective acne treatment, I firmly believe we have the right product, at the right time, for over 50 million acne sufferers in the USA.

"Having successfully launched our direct-to-consumer sales strategy with AcnEase in the US market , we intend to replicate this strategy to the extent justified "by market conditions" in International markets, while we prepare our next product sales initiative to access the US cosmeceutical market expected to potentially reach over $16 billion by 2010.

"Herborium is committed to continue developing a global brand with a strong international distribution network, and the acceptance of AcnEase by the dermatological community is a key development in both product branding and sales growth strategies," Dr. Olszewski concluded.

About Herborium Group, Inc.

Herborium Group, Inc., a botanical therapeutics® company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium harvests its therapeutic candidates from Traditional Chinese Medicine and utilizes Western regulatory, clinical and marketing strategies to successfully introduce the products to the Western markets. The company secured a pipeline of botanical ingredients based products in the areas of dermatological needs, Prostate Health (BPH), Liver Diseases,
Women's Health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, surgical procedures, and other problems. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce.

One of our most important responsibilities is to communicate with shareholders in an open and direct manner. Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends." We cannot promise future returns. Our statements reflect our best judgment at the time they are issued, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events.

Company Contact:
Dr. Agnes P. Olszewski
President & CEO
(201) 647-3757 (201) 647-3757

Posts: 809 | From: florida | Registered: Dec 2008  |  IP: Logged | Report this post to a Moderator
luckylindy
Member


Member Rated:
4
Icon 1 posted      Profile for luckylindy     Send New Private Message       Edit/Delete Post   Reply With Quote 
HBRM: Herborium strives to become the Leader in developing and marketing novel, safe and effective, proprietary botanical therapeutics® (botanical based medicines), and innovative support content which target selected, unmet medical needs for disease treatment, management, and prevention.
Posts: 809 | From: florida | Registered: Dec 2008  |  IP: Logged | Report this post to a Moderator
luckylindy
Member


Member Rated:
4
Icon 1 posted      Profile for luckylindy     Send New Private Message       Edit/Delete Post   Reply With Quote 
Friday, June 04, 2010 9:24:06 AM

Good morning investors and traders. Second verse, same as the first. We are still focusing on Herborium Group Inc., HBRM.PK this morning.

The technicals on this company all point to it trading above $.03 for the first time ever. That could happen as soon as this morning.

http://stockcharts.com/h-sc/ui?s=hbrm

The stock is still in the accumulation mode with 70% of the daily volume as buys. The stock closed May 26th at $.013 on very low volume.

Since that close we have had 5 consecutive sessions averaging 2 million shares daily and closed yesterday at $.0275. This trend is likely to continue into today's trading session as the momentun is still building on this company.

The company is still putting out great news releases to their shareholders as the CEO has committed to keep the company as transparent as possible while still growing the brands and
identity of the company.

This has such long term potential and it is one of the reasons we have this in our portfolio as a long term "hold".

Please read the links below for recent news and shareholder updates:

http://finance.yahoo.com/news/Herborium-Group-Inc-Focuses-iw-2548169042.html?x=0 &.v=1

http://finance.yahoo.com/news/Herborium-Group-Commences-iw-1052859751.html?x=0&. v=1

http://finance.yahoo.com/news/Herborium-Group-Inc-Focuses-pz-3048156823.html?x=0 &.v=1

Posts: 809 | From: florida | Registered: Dec 2008  |  IP: Logged | Report this post to a Moderator
luckylindy
Member


Member Rated:
4
Icon 1 posted      Profile for luckylindy     Send New Private Message       Edit/Delete Post   Reply With Quote 
Herborium offers a robust business model designed to capitalize on the changing landscape in the healthcare sector spearheaded by novel regulatory, market and technological trends, and the cost advantage of natural medicinal products. Herborium’s unique blend of management’s expertise, clinical and regulatory know how in the US, Europe and PRC, diversified proprietary Botanical Therapeutics® portfolio and innovative marketing strategies provide for high-value, high-return opportunity and a strong entry barrier for potential competitors.
Posts: 809 | From: florida | Registered: Dec 2008  |  IP: Logged | Report this post to a Moderator
luckylindy
Member


Member Rated:
4
Icon 1 posted      Profile for luckylindy     Send New Private Message       Edit/Delete Post   Reply With Quote 
Tuesday, June 08, 2010 8:56:56 AM

Good morning subscriber's. This morning we want to alert you again to Herborium Group, Inc. HBRM.PK.

The company is quietly becoming a favorite for micro cap investors as they have been accumulating stock in this company in anticipation of news releases that will allow this stock to run. When the stock does run, and we feel this is going to take place this week, it should test the $.03 mark and cross over it with ease.

The volume has been steady, with an average of 2 million shares traded daily over the last 7 sessions. The chart shows that a bullish pattern is emerging on HBRM.PK. The 5 day MA is over the 13 day MA with the CMF, or Chaikin Money FLow showing an increase of 50% since June 1st.

This signals buy, buy, buy. The bullish trend is but one reason to invest in and trade in this company. Their line of products is another. Herborium Group packs this one two punch like few micro cap companies.

A solid product suite, a strong, low float stock with solid management committed to shareholder success.

We own it and think you should as well.


http://stockcharts.com/h-sc/ui?s=hbrm


Why Herborium Group:


Herborium Group is going to be a player in the botanical healing market.They are quietly staking their claim in this burgeoning 250 billion dollar world wide sector.


We want to refresh your memory as it relates to HBRM.PK


Herborium Group, Inc., is a novel botanical therapeutics® company focused on developing, licensing, and marketing of proprietary, botanical based medicinal products, targeting unmet medical needs. The Company responds to both consumers and healthcare professionals demand for safe, efficacious, all natural medicinal options for treatment and prevention of selected diseases and health concerns.


The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The potential for this market assesses for over $125 Billion in the USA and UK alone.


http://www.herborium.com/indexalt.html


http://finance.yahoo.com/news/Herborium-Group-Commences-iw-1052859751.html?x=0&. v=1


http://finance.yahoo.com/news/Herborium-Group-Inc-Focuses-iw-2548169042.html?x=0 &.v=1


File Msg | Remove Msg | *Private* Reply

Posts: 809 | From: florida | Registered: Dec 2008  |  IP: Logged | Report this post to a Moderator
luckylindy
Member


Member Rated:
4
Icon 1 posted      Profile for luckylindy     Send New Private Message       Edit/Delete Post   Reply With Quote 
mid day chart on HBRM..http://stockcharts.com/h-sc/ui?s=hbrm
Posts: 809 | From: florida | Registered: Dec 2008  |  IP: Logged | Report this post to a Moderator
luckylindy
Member


Member Rated:
4
Icon 1 posted      Profile for luckylindy     Send New Private Message       Edit/Delete Post   Reply With Quote 
Herborium Group, Inc., is a novel botanical therapeutics® company focused on developing, licensing, and marketing of proprietary, botanical based medicinal products, targeting unmet medical needs. The Company responds to both consumers and healthcare professionals demand for safe, efficacious, all natural medicinal options for treatment and prevention of selected diseases and health
Posts: 809 | From: florida | Registered: Dec 2008  |  IP: Logged | Report this post to a Moderator
luckylindy
Member


Member Rated:
4
Icon 1 posted      Profile for luckylindy     Send New Private Message       Edit/Delete Post   Reply With Quote 
The flagship product for Herborium Group Inc. is AcnEase®, a clinically tested and proven effective over the counter acne treatment for people of all ages that are afflicted with acne.

AcnEase® is a proprietary, all herbal, systemically acting botanical therapeutic targeting acne symptom in both females and males of all ages, and has been proven safe and effective through clinical testing. Test results have demonstrated that in adolescent acne, approximately 95% of patients responded positively to AcnEase. In individuals above age 31, the level of effectiveness was 80%. The overall positive response rate to AcnEase was 91%. After more than five years of online sales, Herborium has consistently registered over 95% consumer satisfaction rating.

http://www.acnease.com

Posts: 809 | From: florida | Registered: Dec 2008  |  IP: Logged | Report this post to a Moderator
luckylindy
Member


Member Rated:
4
Icon 1 posted      Profile for luckylindy     Send New Private Message       Edit/Delete Post   Reply With Quote 
Herborium Group Names Dr. Harold Mermelshein MD to Its Scientific Advisory Board
SADDLE BROOK, NJ, Jun 15, 2010 (MARKETWIRE via COMTEX) -- Herborium Group, Inc. (PINKSHEETS: HBRM), a Botanical Therapeutics(TM) company, today announced the appointment of Dr. Harold Mermelshein, MD, a renowned New York dermatologist, to Herborium's Scientific Advisory Board.

"I'm pleased that such a prestigious dermatologist as Dr. Mermelshein has agreed to serve on our Scientific Advisory Board," commented Dr. Agnes P. Olszewski, Herborium Group's president and chief executive officer. "Dr. Mermelshein's career spans more than 30 years, during which time he has distinguished himself as a dedicated, learned advocate in dermatological academia, research, and clinical practice as well as pioneer in using complementary, scientifically based, alternative treatment modalities in clinical practice."

Dr. Mermelshein is Board Certified by, and a standing member of, the American Academy of Dermatology. A magna cum laude alumnus of New York Medical College. Dr. Mermelshein has served as Chief of Residency for New York University Medical Center's Skin and Cancer Unit and, since 1988, as the Associate Clinical Professor of the Center Dermatology Department.

Dr. Olszewski continued, "With Herborium's flagship product, AcnEase(R), now available through an increasing number of distribution channels in the US and abroad, we are focusing on strengthening its consumer and professional brand recognition. Dr. Mermelshein will play a key role in meeting and maintaining only the highest standards expected by medical professionals and consumers, further strengthening Herborium's differential brand advantage. To that end, he will advise management regarding the Company's proactive clinical validation and regulatory strategy speared the U.S. Food and Drug Administration's (FDA) guidance for the botanical drug product industry (FDA Guidance 2004)."

"With Herborium's business model based on clinical testing confirmation of our products efficacy, having Dr. Mermelshein among our team of medical experts will also facilitate further advancement of our clinical testing, and therefore strengthen a differential advantage and marketability of our products growing," concluded Dr. Olszewski.

About Herborium Group, Inc. Herborium Group, Inc., a botanical therapeutics(R) company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium harvests its therapeutic candidates from Traditional Chinese Medicine and utilizes Western regulatory, clinical and marketing strategies to successfully introduce the products to the Western markets. The company secured a pipeline of botanical ingredients based products in the areas of dermatological needs, Prostate Health (BPH), Liver Diseases, Women's Health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, surgical procedures, and other problems. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce.

One of our most important responsibilities is to communicate with shareholders in an open and direct manner. Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends." We cannot promise future returns. Our statements reflect our best judgment at the time they are issued, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events. Adino Energy Corporation urges investors to review the risks and uncertainties contained within its filings with the Securities and Exchange Commission.


Company Contact:
Dr. Agnes P. Olszewski
President & CEO
(201) 647-3757

Posts: 809 | From: florida | Registered: Dec 2008  |  IP: Logged | Report this post to a Moderator
scooz
Member


Rate Member
Icon 1 posted      Profile for scooz     Send New Private Message       Edit/Delete Post   Reply With Quote 
press release
Oct. 21, 2010, 12:00 p.m. EDT

Herborium Engages Investor and Media Relations
SADDLE BROOK, N.J., Oct 21, 2010 (GlobeNewswire via COMTEX) -- Herborium Group, Inc., /quotes/comstock/11i!hbrm (HBRM 0.02, 0.00, -0.57%) www.herborium.com, a Botanical Therapeutics(TM) company, today announced it has retained SmallCap Support Services, a Houston based investor, media, and public relations firm.

"I am pleased to engage SmallCap Support Services to handle our growing investor relations needs and increase our trade & popular press coverage," commented Dr. Agnes P. Olszewski, Herborium Group's president and chief executive officer. "SmallCap ensures all Company information released will be clear and accurately conveyed.

"Herborium develops and markets novel, clinically tested Botanical Therapeutics(R) (botanical medicines), a distinctly separate product classification compared to simple nutraceuticals. Our products' differential advantage rests in clinical testing of its safety and efficacy and drives product development opportunities by the use of U.S. Food & Drug Administration (2004) and European Medicines Agency guidelines.

"Therefore, we required an IR/PR firm with the capacity to develop a working knowledge of Herborium and our products' differential market advantages. After careful consideration, I am pleased to announce SmallCap is such a firm.

"As we finalize marketing plans, I expect further personnel will also be needed to support our new product exposure initiatives, in particular, Herborium's new 2011 U.S. marketing campaign to aggressively promote its flagship product, AcnEase(R)."

AcnEase is a proprietary, botanical therapeutic product taken orally that prevents acne from forming in both females and males of all ages. Furthermore, AcnEase has been proven safe and effective in the treatment of both acne and rosacea through rigorous clinical testing (www.acnease.com).

"Roche's Accutane(R) was the leading prescriptive oral acne medication, until being removed from the market due to serious side-effects. The withdrawal of Accutane has presented Herborium with an enormous opportunity to capture market share with AcnEase -- the only all-natural, safe, and effective oral acne medicine."

"In conclusion, I look forward to soon sharing updates on AcnEase as well as our international sales," Olszewski concluded.

About SmallCap Support Services

SmallCap Support Services is a Houston-based boutique investor relations firm offering a full-range of services to emerging public companies primarily in the Technology, Oil & Gas, Telecom, Medicine, Entertainment, and Defense & Aerospace sectors. SmallCap Support Services works with both development stage and growth stage public companies delivering a full spectrum of affordable investor, public and media relations services. The firm takes on only a small number of honest, hardworking, and innovative clients, and then focuses passionately on their investor relations goals with professionalism, honesty, and integrity of method. For more information, please visit www.smallcapss.com.

About Herborium Group, Inc.

Herborium Group, Inc., a Botanical Therapeutics(R) company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. For more information, please visit www.herborium.com and www.acnease.com.

One of our most important responsibilities is to communicate with shareholders in an open and direct manner. Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends." We cannot promise future returns. Our statements reflect our best judgment at the time they are issued, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events. The Company urges investors to review the risks and uncertainties contained within its filings with the OTC Markets and/or Securities and Exchange Commission.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Herborium Group, Inc.

CONTACT: Herborium Group, Inc.
Media Relations
Steve Haag
(832) 413-6206

Posts: 598 | Registered: Mar 2005  |  IP: Logged | Report this post to a Moderator
scooz
Member


Rate Member
Icon 1 posted      Profile for scooz     Send New Private Message       Edit/Delete Post   Reply With Quote 
Oct. 28, 2010, 10:29 a.m. EDT

Herborium Announces 2011 Product Marketing Strategy
SADDLE BROOK, N.J., Oct 28, 2010 (GlobeNewswire via COMTEX) -- Herborium Group, Inc., /quotes/comstock/11i!hbrm (HBRM 0.02, +0.00, +5.63%) www.herborium.com, a Botanical Therapeutics(TM) company, today announced its 2011 marketing strategy, developed to increase market share of the world's natural medicines market.

"Having been in development for some time now, our 'path-to-market' explains Herborium's core strategy to capture market share -- distinguishing our medicinal products with U.S. Food & Drug Administration (FDA) allowed labeling," commented Dr. Agnes P. Olszewski, Herborium Group's president and chief executive officer. "I believe our three-tier path-to-market, soon available at www.otcmarkets.com, sets forth a sustainable, well thought out approach to development of our product pipeline."

Recent FDA guidelines (fda guidance for industry:Botanical Drug Products), provide a mechanism to perform the clinical research necessary to enable Herborium to advertise medical claims for its proprietary botanical products including AcnEase(R) its flagship product, (www.acnease.com).

"Furthermore, when one considers that Accutane(R), a prescription only systemically acting acne medication marketed by Roche Pharmaceutical, is currently embroiled in class action lawsuits due to its alleged deleterious side effects, the opportunity for AcnEase becomes clear; aggressively establish AcnEase as the only oral, systemically acting acne medication with clinical trial validation of its safety & efficacy and fill Accutane's void."

An estimated 120 million women and men, including more than 30 million adults, suffer from some form of acne in the U.S. and top five European markets. The global pharmaceutical acne market, which was $2.5 billion in 2006, is forecast to grow to over $3 billion by 2016.

"With Herborium's healthy pipeline of additional Botanical Therapeutics currently in development, we expect to apply this overall market strategy to new products as well.

"In conclusion, since the development and marketing of medicines itself tends to be a complicated process, I look forward to soon visiting with our shareholders to answer questions and further explain how we intend to capture market share with this promising new classification of medicines," Olszewski concluded.

About Herborium Group, Inc.

Herborium Group, Inc., a Botanical Therapeutics(R) company, focuses on developing, licensing, and marketing proprietary, botanically based medicinal products to consumers and healthcare professionals. The Company's business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. For more information, please visit www.herborium.com and www.acnease.com.

One of our most important responsibilities is to communicate with shareholders in an open and direct manner. Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends." We cannot promise future returns. Our statements reflect our best judgment at the time they are issued, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events. The Company urges investors to review the risks and uncertainties contained within its filings with the OTC Markets and/or Securities and Exchange Commission.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Herborium Group, Inc.

CONTACT: Herborium Group, Inc.
Dr. Agnes P. Olszewski, President & CEO
(201) 647-3757

Posts: 598 | Registered: Mar 2005  |  IP: Logged | Report this post to a Moderator
   

Quick Reply
Message:

HTML is not enabled.
UBB Code™ is enabled.
UBB Code™ Images not permitted.
Instant Graemlins
   


Post New Topic  New Poll  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2013 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share